Edity Therapeutics

Edity Therapeutics

Biotechnology Research

Rehovot, Israel 1,586 followers

Using human immune cells to deliver therapeutic proteins

About us

Edity is developing a novel delivery platform that uses immune cells to transfer therapeutic proteins to the target cells of patients. Our technology allows for precise modulation of intracellular pathways of disease using a range of proteins including gene editors, immune sensors, enzymes and intrabodies.

Website
www.edity-tx.com
Industry
Biotechnology Research
Company size
11-50 employees
Headquarters
Rehovot, Israel
Type
Privately Held
Founded
2020
Specialties
gene editing, cell therapy, gene therapy, drug delivery, and cancer

Locations

Employees at Edity Therapeutics

Updates

Similar pages

Funding

Edity Therapeutics 3 total rounds

Last Round

Seed
See more info on crunchbase